Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 21533286.
- Also identified by DOI 10.1371/journal.pone.0017520 and PMC identifier 3076368.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
BACKGROUND: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade. OBJECTIVES: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures. METHOD: All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined. RESULTS: Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures. LIMITATIONS: The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult. CONCLUSION: Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.
Medical subject headings
- Dermatitis, Atopic
- Quality of Life
- Severity of Illness Index
- Treatment Outcome